Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMahmoud GhazalMAMohammed AbbaCGCatharina Gerhards

Discussion

Loading...

Member takes

Overview

Retrospective study suggests 7-day venetoclax with decitabine or azacitidine reduces complications in AML, highlighting similar treatment responses.

Key Points

  • A 7-day venetoclax regimen led to lower rates of neutropenia and complications compared to longer treatments.
  • The overall response rate across analyzed patients was 74%, with no significant differences in remission status by treatment duration.
  • Assessment using retrospective data from 61 patients with acute myeloid leukemia or higher-risk myelodysplastic neoplasms was performed.
  • Shorter venetoclax exposure may offer effective treatment with fewer toxicities, suggesting potential for broader application.

Cite This Study

Ghazal et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e455https://doi.org/10.1182/blood-2025-1622
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  2. 2Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study2025
  3. 3Venetoclax combined with azacitidine in elderly acute myeloid leukemia: A retrospective comparison of 14-day vs 28-day dosing regimens2025 · 2 citations
  4. 4Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis2025
  5. 5Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025